Oncoceutics, Inc. is a drug discovery and development company targeting the most potent suppressor pathways in human cancer. The company’s leadership team represents a group of drug development executives with unparalleled success in the industry. Central to Oncoceutics’ scientific and technology base is a focus on drug discovery that engages natural potent tumor suppressor pathways. The first lead compound that came out of this program is ONC201, a small molecule that possesses significant anti-tumor activity in a number of different types of human cancer through a unique mechanism of action. The compelling preclinical efficacy and safety of ONC201 along with its favorable chemical properties offer a high potential for safe and meaningful therapeutic benefit to cancer patients in numerous clinical settings. Clinical lead indications for ONC201 are being evaluated in a series of clinical trials that are in various stages of initiation at leading cancer centers around the world.
Chief Executive Officer
Wolfgang Oster, M.D., Ph.D. has an extensive managerial and medical background. He has undergone medical training in Europe and the U.S., is board certified in internal medicine, hematology/oncology, and has served as an Adjunct Professor of Medicine at Brown and in Freiburg, Germany.
"Chief Business Officer
Lee Schalop, M.D. is the company’s chief business officer, a role he has held since graduating with a doctor of medicine degree from the Albert Einstein College of Medicine in 2008. Prior to attending medical school, Dr. Schalop spent more than 19 years in the financial industry at a number of major Wall Street firms, including Morgan Stanley, J.P. Morgan, Credit Suisse and Banc of
Chief Development Officer
Martin Stogniew, Ph.D. brings 32 years of senior executive experience in the pharmaceutical industry and has served as an independent member of the Board of Directors for Provid Pharmaceuticals. Marty has made significant contributions resulting in FDA approval of eight New Drug Applications, issuance of twenty-seven US patents, and closure of four major M&A deals totaling ~3 billion dollars.
Director of Development
Joshua Allen, Ph.D. is a cancer researcher that brings deep technical expertise as a co-inventor of ONC201 who discovered the molecule in the lab and has studied several cancer therapeutics for years.